Supplementary
Patients assigned to the TPF/CRT arm were further randomly assigned to receive either cisplatin/5-FU or cetuximab for CRT. VOLUME 48 NUMBER 3 JULy 2016 3 Low ( These trials have not yet been published.

Hematologic
Neutropenia [9, 11, 13, 15, 21] Febrile neutropenia [10, 13, 15, 21] Anemia [9, 11, 13, 15, 21] Thrombocytopenia [9, 11, 13, 15, 21] Nonhematologic Mucositis/stomatitis [9, 11, 13, 15, 21] Nausea [9, 11, 13, 21] Vomiting [9, 11, 13, 21] Supplementary Fig. S2 . Funnel plots comparing HRs for OS (A) and PFS (B). HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
